{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Overall Response Rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.9"}]}],"title":"Stringent Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Overall response is defined as the percentage of participants who have a partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) defined by the International Myeloma Working Group Criteria for Multiple Myeloma out of all evaluable participants. PR is ≥50% reduction if serum M-protein and reduction in 24-hour(h) urinary M-protein by ≥90% or to \\<200mg per 24h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis. CR is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≥5% plasma cells in bone marrow. sCR is complete response plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.","groups":[{"description":"Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)\n\nCarfilzomib intravenous (IV) 20-36 mg/m\\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.\n\nRevlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"54/55 participants are evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"time measurement criteria are met for best response until the first date that recurrent or progressive disease is met, up to 5 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}